Here’s Why You Can’t Compare Vaccine Results Between Johnson & Johnson, Pfizer, and Moderna

1 min read

Johnson & Johnson (NYSE: JNJ) announced late-stage results for its COVID-19 vaccine in late January. The immediate focus was on the vaccine’s efficacy, which was markedly lower than efficacy levels reported by Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) for their COVID-19 vaccines.

In this Motley Fool Live video recorded on Feb. 1, 2021, Motley Fool contributors Keith Speights and Danny Vena discuss one reason why you can’t really compare J&J’s results with the results reported by Pfizer and Moderna.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

1 Under-the-Radar SaaS IPO to Watch in 2021

Next Story

3 Ways to Go Broke in the Stock Market — and How to Invest Successfully Instead

Latest from Blog